Cited by 286Lipoproteins and Cardiovascular HealthMedication Adherence and ComplianceHealth Promotion and Cardiovascular Prevention

Patient‐Reported Reasons for Declining or Discontinuing Statin Therapy: Insights From the PALM Registry

Open access
Bradley, Corey K., Wang, Tracy Y., Li, Shuang, Robinson, Jennifer G., Roger, Veronique L., Goldberg, Anne C., Virani, Salim S., Louie, Michael J. +3 more·2019·Journal of the American Heart Association

Abstract

Background: Many adults eligible for statin therapy for cardiovascular disease prevention are untreated. Our objective was to investigate patient‐reported reasons for statin underutilization, including noninitiation, refusal, and discontinuation. Methods and Results: This study included the 5693 adults recommended for statin therapy in the PALM (Patient and Provider Assessment of Lipid Management) registry. Patient surveys evaluated statin experience, reasons for declining or discontinuing statins, and beliefs about statins and cardiovascular disease risk. Overall, 1511 of 5693 adults (26.5%) were not on treatment. Of those not on a statin, 894 (59.2%) reported never being offered a statin, 153 (10.1%) declined a statin, and 464 (30.7%) had discontinued therapy. Women (relative risk: 1.22), black adults (relative risk: 1.48), and those without insurance (relative risk: 1.38) were most likely to report never being offered a statin. Fear of side effects and perceived side effects were the most common reasons cited for declining or discontinuing a statin. Compared with statin users, those who declined or discontinued statins were less likely to believe statins are safe (70.4% of current users vs. 36.9% of those who declined and 37.4% of those who discontinued) or effective (86.3%, 67.4%, and 69.1%, respectively). Willingness to take a statin was high; 67.7% of those never offered and 59.7% of patients who discontinued a statin would consider initiating or retrying a statin. Conclusions: More than half of patients eligible for statin therapy but not on treatment reported never being offered one by their doctor. Concern about side effects was the leading reason for statin refusal or discontinuation. Many patients were willing to reconsider statin therapy if offered.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/jaha.118.011765

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In a registry that studied reasons why eligible patients were not taking a statin, 59% reported never being offered treatment, 10% declined a statin, and 31% discontinued therapy.

    “In a registry that studied reasons why eligible patients were not taking a statin, 59% reported never being offered treatment, 10% declined a statin, and 31% discontinued therapy.18”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [21]Kashani A, Phillips CO, Foody JM, Wang Y, Mangalmurti S, Ko DT, Krumholz HM. Risks associated with statin therapy. Circulation. 2006; 114: 2788– 2797. 17159064

Cited by

Sorted by citations

Authors
Bradley, C. K., Wang, T. Y., Li, S., Robinson, J. G., Roger, V. L., Goldberg, A. C., Virani, S. S., Louie, M. J., Lee, L. V., Peterson, E. D., & Navar, A. M.
Affiliations
  • Duke University (US)
  • University of Iowa (US)
  • Mayo Clinic (US)
  • Washington University in St. Louis (US)
  • Baylor College of Medicine (US)
  • Regeneron (United States) (US)
  • Sanofi (United States) (US)
  • Department of Medicine and Duke Clinical Research Institute Duke University School of Medicine Durham NC
Corresponding author
Bradley, Corey K.
Venue
Journal of the American Heart Association
Published
2019-04-02
Volume
8
Issue
7
Pages
e011765-e011765
ISSN
2047-9980 (ISSN-L)
OpenAlex
W2923928888
Cited by
286
References
25
Citations by year
2026: 34 · 2025: 41 · 2024: 56 · 2023: 43 · 2022: 30 · 2021: 41 · 2020: 28 · 2019: 13
FWCI
26.76
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Journal of the American Heart Association (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
  • eCommons - AKU (Aga Khan University) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Heart, Lung, and Blood Institute (K01HL133416)
  • Duke Clinical Research Institute
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
statin therapy, statin discontinuation, fear of side effects, cardiovascular disease prevention, lipid control, health beliefs, racial and ethnic disparities, insurance status
MeSH terms
Patient Reported Outcome Measures, Adult, Aged, Attitude to Health, Black or African American, Cardiovascular Diseases, Fear, Female, Humans, Male, Middle Aged, Motivation, Practice Patterns, Physicians', Primary Prevention, Registries, Sex Factors, United States, Treatment Refusal, Hydroxymethylglutaryl-CoA Reductase Inhibitors, White People, Atherosclerosis, Healthcare Disparities, Medication Adherence, Secondary Prevention, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review